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Abstract
Better estimates of changes in the level and structure of national, regional, and global expenditures on health research
and development (R&D) are needed as an important source of information for advancing countries’ health research
policies. However, such estimates are difficult to compile and comparison between countries needs careful calibration.
We outline the steps that need to be taken to make reliable estimates of trends in countries’ expenditures on health
R&D, describe that an ideal approach would involve the use of international sets of deflators and exchange rates that
are specific to health R&D activities, and explain which methods should be used given the current absence of such
health R&D-specific deflators and exchange rates. Finally, we describe what should be the way forward in improving
our ability to make reliable estimates of trends in countries’ health R&D expenditures.
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Difficulties in comparing countries’ health-related
R&D expenditures
Estimates of changes in the level and structure of na-
tional, regional, and global expenditures on health re-
search and development (R&D) are an important source
of information for advancing countries’ health research
policies. However, such estimates are difficult to compile
and comparison between countries needs careful calibra-
tion [1].
At present, the availability of user-friendly guidelines
on how to compile and compare such data is limited
outside two technical annexes to the international stand-
ard practice for surveys of R&D known as the Frascati
Manual (one on identifying health R&D spending and
the other on R&D deflators and currency converters)
[2,3]. These annexes are not always identified by online
searches and are essentially written by and for the ex-
perts who collect R&D statistics, rather than for analysts
from within the health research system who want to use
them.
The difficulties concerned can be illustrated by a com-
parison between two recent efforts to compile and com-
pare national contributions to world-wide expenditures
on health-related R&D. Chakma et al. [4] recently pub-
lished an article comparing decreases in spending on
health R&D in the United States between 2007 and 2012
to increases in countries in Asia-Oceania in a world-
wide context. The estimates developed by Chakma et al.
[4] appear to differ markedly from our own published
findings of an extensive mapping of all countries’ expen-
ditures on health R&D in 2009, which also examined the
distribution between low-, middle-, and high-income
countries [5]. Here, we set out how these differences oc-
curred and identify the topics on which guidance is
needed.
Exercises to estimate countries’ expenditures on health
R&D involve two stages. First, national and international
sources of relevant data need to be tracked down and
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the health-related categories of expenditure extracted. Sec-
ond, these health-related expenditures need to be con-
verted to comparable price levels over time using a
common currency between countries. The data sources
used in our own recent study varied in some cases from
those used by Chakma et al. [4], but it is at the second
stage – data conversion – that the main differences arose.
Absence of relevant price indices and currency
convertors
To convert countries’ health-related R&D expenditures
to comparable price levels, ideally one needs exchange
rates that are specific to the “basket of goods” used in
health R&D activities. To be able to compare these ex-
penditures over time also requires indices that describe
how the price of that basket of goods deflates or inflates
over time in each country. Unfortunately, there are cur-
rently no standard international sets of deflators or ex-
change rates based on the basket of goods used in R&D
activities. As a result, there is no choice but to choose
proxy series of price indices and currency convertors,
and to opt for the “least unsatisfactory” approach. For
countries with developed sets of R&D statistics, health
accounts, and general economic statistics, there is a
range of possible proxies from which to choose. How-
ever, for a world-wide comparison, one needs to select
proxy series which are available for all countries, thus re-
ducing the available options considerably. In this article,
we describe what the “least unsatisfactory” option is for
converting health-related R&D expenditures to one
common currency and for comparing these expenditures
over time.
Converting health-related R&D expenditures to
one common currency
When comparing health R&D expenditures between
countries they must be put in a common currency. In the
absence of special “health R&D exchange rates” based on
the comparative costs of the inputs into the activity, the
two conversion rates most readily available are current ex-
change rates and GDP purchasing power parities (PPPs).
Current exchange rates mainly reflect the cost of traded
goods and services rather than domestic activities such as
R&D and may also be affected by currency speculation,
political events, and government controls (Sidebar on
“Comparing international R&D expenditures” in [6]). GDP
PPPs, on the other hand, were developed to provide better
convertors for comparisons of national wealth as mea-
sured by GDP [7]. A relatively recent detailed study on the
topic showed that these GDP PPPs do not reflect the cost
of R&D very accurately as compared with estimated R&D
PPPs [8]. However, the study covers only the manufactur-
ing industry in six developed countries and two years
(1987 and 1997). For world-wide comparisons one must
still make a “least unsatisfactory” choice between current
exchange rates and GDP PPPs. The WHO health accounts
database offers both options for total health expenditures.
Chakma et al. [4] chose current exchange rates for their
main tables; we followed the recommendation of the
Frascati manual and used GDP PPPs (as Chakma et al.
did in a pie-chart in the online annex to their paper
[4]). Using current exchange rates instead of PPPs un-
derestimates the contribution of countries such as
China and India, because, for the reasons given above,
exchange rates in these countries overstate the cost of
domestic activities and thus probably of R&D.
Comparing trends in health R&D expenditures
over time
When comparing trends in health R&D expenditures
over time in different countries it is necessary to adjust
the current price data in order to exclude the contribu-
tion of inflation to apparent growth. To do so, one needs
an index of the trend in the price of the inputs into
health-related R&D in each country. The only long
established example of such an index is the special R&D
deflator used in the annual discussions of the budget of
the US National Institutes of Health (NIH) [9]. It, like
other estimates of trends in R&D costs in developed
countries [10], shows that the price of the “basket of
goods” used in R&D grows at a different rate, usually
higher, than the average of prices included in the implicit
GDP price index. In the absence of a specific health
R&D index, the main options for other countries are to
use the implicit GDP price index, which is currently rec-
ommended by the Frascati manual, or to use the con-
sumer price index, which suffers from the same defects
as the GDP deflator for R&D analysis purposes (i.e., that
it is not specific to R&D). Chakma et al. [4] chose to de-
flate the health R&D expenditures of all countries using
the US NIH price index. This is questionable as the gen-
eral level of inflation varies between countries more than
the difference between the R&D and the general price
index in the United States. Thus, the use of the NIH
R&D price index flatters countries with high inflation,
such as India, and underestimates growth in health R&D
funding in countries where general prices were stagnant,
such as Taiwan.
Combining prices and currency convertors
Finally, in this exercise we need to apply the price indi-
ces and currency converters we have selected to our ori-
ginal expenditure series in national currency. These
must be combined in a way which avoids inappropriate
interactions between the price index and the currency
converter. The established method is to first deflate the
national currency data and then to convert the deflated
data for all years to a common currency using an
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appropriate exchange rate for the base year for the price
index. In the study by Chakma et al. [4], the data were first
converted year by year to US dollars and then deflated
using 2012 as the base year. This method overestimates
growth in funding in countries such as Japan, where R&D
spending grew little in national currency between 2007
and 2012 while the value of the yen appreciated. Addition-
ally, it underestimates the increase in countries such as
South Korea where the national currency fell against the
dollar over the same period.
Effect of using different analytical methods and
data sources to compare trends in health-related
R&D between the USA and Oceania
Using data derived from the text table in the article by
Chakma et al. [4], we have recalculated the health R&D
expenditures for the USA and Asia-Oceania using the
methods described above, which should be considered
current best practice (Table 1). Each stage of this re-
calculation has different impacts on each country. Ul-
timately, the gross increase in health R&D expenditure
in fixed price PPP dollars in the Asia-Oceania zone is
only slightly lower than in the original article by Chakma
et al. [4]. However, the balance between the countries
clearly changes. China now has the largest growth,
followed by South Korea. In India growth is higher, but
in Japan and Australia less. These results support the au-
thors’ thesis, though the decline in the United States is
not so marked.
Besides different approaches to analysis, the use of dif-
ferent data sources can also lead to diverging estimates
of countries’ health R&D expenditures. To see whether
the use of an alternative dataset changes the results of
the analysis, we have also calculated the trends in health
R&D expenditures in the countries in Asia-Oceania
using our data [5] instead of Chakma et al.’s [4], and ap-
plying both their method and the best practice methods
of deflation and currency conversion (Table 1). This ana-
lysis confirms the growth in health R&D expenditures in
Asia-Oceania, though in most countries at a slightly
lower level. This difference likely stems from our data
being derived from standard surveys of the performers
of R&D (supplementary appendix to [5]), whose results
tend to change less rapidly than data taken from the re-
ports of funding bodies used in a number of cases by
Chakma et al. (supplementary table one in [4]). The rea-
sons for differences between data derived from funder
and performer reported sources are described in the
Frascati Manual [12].
Conclusions
In conclusion, estimates of national and global expendi-
tures on health R&D can vary significantly depending on
the methods that are used in the analysis. Making reli-
able estimates is currently hampered by the absence of
standard health R&D price indices and exchange rates,
though general work to redress this absence is currently
in progress in the context of treating R&D as an intan-
gible investment in the latest edition of the System of
National Accounts [13]. Hopefully, following the recent
decision by WHO Member States to establish a Global
Health R&D Observatory, progress will be made in the
future on developing and agreeing on such standards
[14,15]. This will be important if we are to make
Table 1 Changes in estimated health R&D spending between 2007 and 2012 for countries in Asia-Oceania, the USA
and Canada, using two methods and two data sources (in billion US dollars)
Country Data from Chakma et al. [4] Data from Røttingen et al. [5]
Current exchange rates
and NIH 2012 prices
2012 PPP exchange rates
and 2012 GDP prices
Current exchange rates
and NIH 2012 prices
2012 PPP exchange rates
and 2012 GDP prices
USA −12.0 −4.0 – *
Canada −0.7 −0.7 −1.0 −1.0
Asia-Oceania 20.9 19.2 17.0 15.0
Japan 9.0 2.8 7.3 2.4
China 6.4 8.7 4.3 5.6
South Korea 2.5 4.3 2.2 3.9
Australia 1.7 0.4 2.2 0.8
India 0.6 1.6 0.5 1.4
Other Asia-Pacific** 0.6 0.7 0.5 0.9
Column 1 is the original data from Chakma et al. [4]. In column 2, we have applied analytical approaches to their data that are currently considered best practice.
In columns 3 and 4 we applied both their method and the best practice approaches to time series compiled on the same basis as the 2009 data in our own
study, which draw on different data sources in some cases. [5].
*We were unable to estimate the growth in health related R&D expenditure in the United States on the same basis as we used in our article as the underlying
figures for industry were only collected for 2008 and 2009 [11].
**Column 2 is recalculated from the data for Singapore and Taiwan in the pie-chart in the appendix of the article by Chakma et al. [4] combined with the growth
rates in the text chart as the two countries are grouped in the text table used for the other countries.
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progress in generating data and indicators that are truly
comparable and capable of influencing countries’ health
research policies. In the meantime, in the absence of
R&D-specific price indices and exchange rates, the devel-
opment of user-friendly interim guidelines on selecting
and applying the available price indices and convertors
would be a useful first step and a potential output from
the newly established Observatory [14].
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